Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Fosfomycin
2. Fosfomycin Trometamol Salt
3. Fosfomycin Tromethamine
4. Phosphomycin
5. Phosphonomycin
6. Tromethamine, Fosfomycin
1. 78964-85-9 (tromethamine)
2. [1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azanium;hydroxy-[(2r,3s)-3-methyloxiran-2-yl]phosphinate
3. Tromethamine-fosfomycin
4. Fosfotricin
5. Monurol Sachet
6. Fosfomycin Compd. With Trometamol
7. Einecs 279-018-8
8. Fosfomycin Tromethaminel
9. Unii-7fxw6u30gy
10. Akos015896108
11. Ac-4209
12. Ks-1266
13. (2r-cis)-(3-methyloxiranyl)phosphonic Acid, Compound With 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)
| Molecular Weight | 259.19 g/mol |
|---|---|
| Molecular Formula | C7H18NO7P |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 259.08208891 g/mol |
| Monoisotopic Mass | 259.08208891 g/mol |
| Topological Polar Surface Area | 161 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 190 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Bioquim: An European GMP-certified company manufacturing bulk APIs, specializing in sterile lyophilization and chemical synthesis.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-11-21
Pay. Date : 2024-10-18
DMF Number : 40335
Submission : 2024-09-27
Status : Active
Type : II
NDC Package Code : 69037-0066
Start Marketing Date : 1996-12-19
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
Certificate Number : CEP 2022-327 - Rev 01
Issue Date : 2025-09-15
Type : Chemical
Substance Number : 1425
Status : Valid
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2024-11-21
Pay. Date : 2024-10-18
DMF Number : 40335
Submission : 2024-09-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-06-20
Pay. Date : 2016-12-22
DMF Number : 31195
Submission : 2017-02-24
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11582
Submission : 1995-07-10
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10891
Submission : 1994-04-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-01-04
Pay. Date : 2017-09-27
DMF Number : 31656
Submission : 2017-04-04
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40460
Submission : 2024-09-27
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-04-05
Pay. Date : 2018-12-06
DMF Number : 33294
Submission : 2018-11-02
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fosfomycin, an antibiotic, targets UDP-N-acetylglucosamine 1-carboxyvinyltransferase, showing promise in treating complicated urinary tract infections (cUTI).
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Contepo
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Meitheal Pharmaceuticals Gets FDA Approval for CONTEPO™ in Patients with cUTI, Including AP
Details : Fosfomycin, an antibiotic, targets UDP-N-acetylglucosamine 1-carboxyvinyltransferase, showing promise in treating complicated urinary tract infections (cUTI).
Product Name : Contepo
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 04, 2025

Details:
Uroxin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Uroxin,Fosfomycin Trometamol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: pharmaSuisse
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2024

Lead Product(s) : Uroxin,Fosfomycin Trometamol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : pharmaSuisse
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Collagen, Propolis Plus Quercetin (Proqutin®), Bacillus Coagulans, Hyaluronic Acid ...
Details : Uroxin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2024

Details:
Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Cystitis.
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Antibiotic
Sponsor: Petrovax
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 14, 2023

Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Petrovax
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Uronext® in Women With Cystitis
Details : Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Cystitis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 14, 2023

Details:
Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: ZonMw | Saltro
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2022

Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : ZonMw | Saltro
Deal Size : Inapplicable
Deal Type : Inapplicable
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
Details : Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 24, 2022

Details:
Fosfomycin trometamol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Fosfomycin Trometamol,Nitrofurantoin,Pivmecillinam Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Balearic Islands Health Service | Instituto de Investigación Sanitaria Aragón | Gerencia de Atención Primaria, Madrid
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 13, 2021

Lead Product(s) : Fosfomycin Trometamol,Nitrofurantoin,Pivmecillinam Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Balearic Islands Health Service | Instituto de Investigación Sanitaria Aragón | Gerencia de Atención Primaria, Madrid
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fosfomycin trometamol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2021

Details:
Fosfomycin Tromethamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Laboratorios Senosiain
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2019

Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Laboratorios Senosiain
Deal Size : Inapplicable
Deal Type : Inapplicable
Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)
Details : Fosfomycin Tromethamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2019

Details:
Ciprofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infections.
Lead Product(s): Ciprofloxacin,Trimethoprim,Sulfamethoxazole,Fosfomycin Trometamol,Pivmecillinam Hydrochloride,Amoxicillin Trihydrate,Clavulanate Acid
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibiotic
Sponsor: ZonMw
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 24, 2017

Lead Product(s) : Ciprofloxacin, Trimethoprim, Sulfamethoxazole, Fosfomycin Trometamol, Pivmecillinam Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
Details : Ciprofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 24, 2017

Details:
Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Amikacin,Fosfomycin Trometamol
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 16, 2016

Lead Product(s) : Amikacin,Fosfomycin Trometamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers
Details : Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 16, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Centaurium Erythraea is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Centaurium Erythraea,Levisticum Officinale,Rosmarinus Officinalis,Fosfomycin Trometamol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Centaurium Erythraea,Levisticum Officinale,Rosmarinus Officinalis,Fosfomycin Trometamol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs
Details : Centaurium Erythraea is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 24, 2015

Details:
Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pneumonia, Bacterial.
Lead Product(s): Amikacin,Fosfomycin Trometamol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 18, 2014

Lead Product(s) : Amikacin,Fosfomycin Trometamol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pneumonia, Bacterial.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 18, 2014

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fosfomycin Phenylethylamine Salt
CAS Number : 25383-07-7
End Use API : Fosfomycin Trometamol
About The Company : Hy-Gro Chemicals Pharmtek Pvt. Ltd. (Hy-Gro) is a fast growing pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Ad...

CAS Number : 25383-07-7
End Use API : Fosfomycin Trometamol
About The Company : Dorrapharma is engaged in R&D, manufacture and market of intermediate, API (Active Pharmaceutical Ingredients) and formulation. We stick to raise the value both...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
85
PharmaCompass offers a list of Fosfomycin Trometamol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fosfomycin Trometamol manufacturer or Fosfomycin Trometamol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fosfomycin Trometamol manufacturer or Fosfomycin Trometamol supplier.
PharmaCompass also assists you with knowing the Fosfomycin Trometamol API Price utilized in the formulation of products. Fosfomycin Trometamol API Price is not always fixed or binding as the Fosfomycin Trometamol Price is obtained through a variety of data sources. The Fosfomycin Trometamol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Monuril manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Monuril, including repackagers and relabelers. The FDA regulates Monuril manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Monuril API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Monuril manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Monuril supplier is an individual or a company that provides Monuril active pharmaceutical ingredient (API) or Monuril finished formulations upon request. The Monuril suppliers may include Monuril API manufacturers, exporters, distributors and traders.
click here to find a list of Monuril suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Monuril DMF (Drug Master File) is a document detailing the whole manufacturing process of Monuril active pharmaceutical ingredient (API) in detail. Different forms of Monuril DMFs exist exist since differing nations have different regulations, such as Monuril USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Monuril DMF submitted to regulatory agencies in the US is known as a USDMF. Monuril USDMF includes data on Monuril's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Monuril USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Monuril suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Monuril Drug Master File in Japan (Monuril JDMF) empowers Monuril API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Monuril JDMF during the approval evaluation for pharmaceutical products. At the time of Monuril JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Monuril suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Monuril Drug Master File in Korea (Monuril KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Monuril. The MFDS reviews the Monuril KDMF as part of the drug registration process and uses the information provided in the Monuril KDMF to evaluate the safety and efficacy of the drug.
After submitting a Monuril KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Monuril API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Monuril suppliers with KDMF on PharmaCompass.
A Monuril CEP of the European Pharmacopoeia monograph is often referred to as a Monuril Certificate of Suitability (COS). The purpose of a Monuril CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Monuril EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Monuril to their clients by showing that a Monuril CEP has been issued for it. The manufacturer submits a Monuril CEP (COS) as part of the market authorization procedure, and it takes on the role of a Monuril CEP holder for the record. Additionally, the data presented in the Monuril CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Monuril DMF.
A Monuril CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Monuril CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Monuril suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Monuril as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Monuril API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Monuril as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Monuril and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Monuril NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Monuril suppliers with NDC on PharmaCompass.
Monuril Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Monuril GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Monuril GMP manufacturer or Monuril GMP API supplier for your needs.
A Monuril CoA (Certificate of Analysis) is a formal document that attests to Monuril's compliance with Monuril specifications and serves as a tool for batch-level quality control.
Monuril CoA mostly includes findings from lab analyses of a specific batch. For each Monuril CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Monuril may be tested according to a variety of international standards, such as European Pharmacopoeia (Monuril EP), Monuril JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Monuril USP).